

### III. 研究成果の刊行に関する一覧表

## 別添5

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書籍名	出版社名	出版地	出版年	ページ
森下英理子	IV出血・血栓症疾患、8)深部静脈血栓症	松村到、張替秀郎、神田善伸	血液疾患最新の治療2023-2025	南江堂	東京	2022	
落合正行、石村匡崇、大賀正一	救急・集中治療 特集「徹底ガイド DICのすべて 2022-‘23」  VIII. 基本病態と治療 57. 新生児・小児	丸藤哲	救急・集中治療	総合医学社	東京	2022	607-609

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Imai Y, Nagaya S, Araiso Y, Meguro-Horiike M, Togashi T, Ohmori K, Makita Y, Sato E, Yujiri T, Nagamori Y, Horike SI, Watanabe A, Morishita E.	Identification and functional analysis of three novel genetic variants resulting in premature termination codons in three unrelated patients with hereditary antithrombin deficiency.	Int J Hematol	117(4)	523-529	2023
Marumo A, Sugihara H, Omiya I, Morishita E	Relapse of acquired hemophilia A following COVID-19.	J Nippon Med Sch		doi: 10.1272/jnms.2023_90-609. Online ahead	2023
Yamada S, Sugaya Y, Morishita E, Asakura H	Effect of Anticoagulant/Antifibrinolytic Combination Therapy on Enhanced Fibrinolytic-Type Disseminated Intravascular Coagulation in End-of-Life Stage Solid Tumor Patients.	J Palliat Med	26(2)	307-311	2023

Arahata M, A sakura H, Mo rishi E, M inami S, Shi mizu Y	Identification and Prognostic ication of End-of-Life State Using a Japanese Guideline-Based ased Diagnostic Method: A Diagnostic Accuracy Study.	Int J Gen Med	16	23–36	2023
Moore GW, Ca stoldi E, Te ruya J, Mori shita E, Adc ock DM	Adcock DM. Factor V Leiden-independent activated protein C resistance: Communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee.	J Thromb Haemost	21(1)	164–174	2023
Tiago J S Lo pes, Ricardo A Rios, Tat iane N Rios, Brenno M Al encar, Marco s V Ferreira a, Morishita E	Computational analyses reveal fundamental properties of the AT structure related to thrombosis.	Bioinformatics advances.	3(1)	vbac098	2023
Noiri JI, Ma tsuzoe H, Na gaya S, Nish io R, Matsum oto D, Takai shi H, Moris hita E	A case of venous thromboembolism caused by protein C deficiency due to a novel gene mutation.	J Cardiol Case	26(5)	360–363	2022
Yamanaka Y, Yo kota I, Yao sumoto A, Mo rishi E, Hir oriuchi H	Time of Day of Vaccination Does Not Associate With SARS-CoV-2 Antibody Titer Following First Dose of mRNA COVID-19 Vaccine	J Biol Rhythms	37(6)	700–706	2022
Kobayashi T, Su giura K, Ojima T, Hir ai K, Morishita E	Peripartum management of hereditary thrombophilia: results of primary surveillance in Japan.	Int J Hematol	116(3)	364–371	2022

Nakamura S, Sugasaki M, Souri M, Aka zawa H, Soga wa M, Hori T, Yamagami H, Takishita M, Aihara K I, Abe M, Ya sumoto A, Mo rishi E, I chinose A	Autoimmune Acquired Factor X III/13 Deficiency after SARS CoV-2 mRNA Vaccination.	Thromb Haemost		doi: 10.1055 /a-1863-726 5. Online ah ead of prin t.	2022
Takatsuki M, Araki T, Ka nno A, Yasum oto A, Moris hita E, Shio ta H	Thrombosis with Thrombocytopenia Syndrome after ChAdOx1 nCoV-19 vaccination.	Rinsho Shinkeigaku	62(6)	487-491	2022
Deloughery T G, Hunt BJ, Barnes GD, Crt of inherite onnors JM; Wa TD Steering Committee.	A call to action: MTHFR poly morphisms should not be a pa morphism of inherited thrombophilia testing.	Res Pract Thromb Haemost	6(4)	e12739	2022
Kaneshige R, Motoki Y, Y oshida M, Ok u K, Morishi ta E, Ieko M, Ichihara K, Nojima J.	Determination of diagnostic threshold in harmonization a nd comparison of clinical ut ility for five major antiph ospholipid antibody assays us ed in Japan.	J Clin Lab Ana l	36(5)	e24340	2022
森下英理子, 林 朋恵	血液・造血器疾患 血栓性血小 板減少性紫斑病	検査と技術	51(3増大 号)	259-265	2023
森下英理子	COVID-19およびCovid-19ワクチ ンと血栓症の関係について教 えてください	老年医学	60	153-157	2022
森下英理子	出血傾向	日本医師会雑誌 血液疾患のすべ て	151特 (1)	72-73	2022
森下英理子	血栓症	日本医師会雑誌 血液疾患のすべ て	151特 (1)	74-75	2022

森下英理子	血友病類縁疾患と線溶異常による出血性疾患	日本医師会雑誌 血液疾患のすべて	151特(1)	317-319	2022
森下英理子	遺伝性血栓性素因	日本医師会雑誌 血液疾患のすべて	151特(1)	97-101	2022
森下英理子	COVID-19の血栓性病態	Land-Mark in Thrombosis & Haemostasis	2	97-100	2022
森下英理子	直接型経口抗凝固薬(DOAC)使用時の凝固関連検査の乖離(AT活性およびPS活性検査試薬)	臨床検査	66(10)	1220-1223	2022
森下英理子	C O V I D-19の抗血栓療法～2022年7月に公表された国際血栓止血学会ガイドラインを中心に～	Thrombosis Medicine	12 (4)	55-59	2022
森下英理子	COVID-19による血栓症	糖尿病・内分泌代謝科	55 (6)	736-743	2022
Uwamino Y, Y okoyama T, S himura T, Ni shimura T, S ato Y, Wakui M, Kosaki K, Hasegawa N, <u>Murata M</u>	The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals	Vaccine	40(13)	1928-1931	2022

Abe K, Kabe Y, Uchiyama S, Iwasaki Y, Ishizu H, Uwamino Y, Takenouchi T, Uno S, Ishii M, Maruno T, Noda M, <u>Murata M</u> , Hasegawa N, Saya H, Kitagawa Y, Fukunaga K, Amagi M, Siomi H, Suematsu M, Kosaki K Keio Donner Project	Pro108Ser mutation of SARS-CoV-2 3CLpro reduces the enzyme activity and ameliorates the clinical severity of COVID-19	Sci Rep	12(1)	1299	2022	
Wakui M, Uwamino Y, Yatabe Y, Nakagawa T, Sakai A, Kurafuji T, Shibata A, Tomita Y, Noguchi M, Tanabe A, Arai T, Ohno A, Yokota H, Uno S, Yamashawa W, Sato Y, Ikeda M, Yoshimura A, Hasegawa N, Saya H, <u>Murata M</u>	Assessing anti-SARS-CoV-2 cellular immunity in 571 vaccines by using an IFN- $\gamma$ release assay	Eur J Immunol	52(12)	1961–1971	2022	

Mise-Omata S, Ikeda M, Takeshita M, Uwamino Y, Wakui M, Arai T, Yoshifumi ji A, Murano K, Siomi H, Nakagawara K, Ohyagi M, Ando M, Has egawa N, Say a H, <u>Murata</u> M, Fukunaga K, Namkoong H, Lu X , Yamasaki S, Y oshimura A	Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant	J Immunol	209(11)	2104-2113	2022
Uwamino Y, Kurofuji T, Takato K, Sakai A, Tanabe A, Noguchi M, Yatabe Y, Arai T, Ohno A, Tomita Y, Shibata A, Yokota H, Yamasawa W, Namkoong H, Sato Y, Has egawa N, Wakui M, <u>Murata</u> M	Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine	Vaccine	40(32)	4538-4543	2022
Yamada Y, Chubachi S, Yamada M, Yokoyama Y, Tanabe A, Matsukawa S, Niijima Y, <u>Murata</u> M, Fukunaga K, Jinzaki M	Comparison of lung, lobe, and airway volumes between supine and upright computed tomography and their correlation with pulmonary function test in patients with chronic obstructive pulmonary disease	Respiration	101	1110-1120	2022

Uwamino Y, Kuraufuji T, Ato Y, Shibata A, Tanabe A, Yatabe Y, Noguchi M, Arai T, Ohno A, Yokota H, Yamasawa W, Uno S, Nishimura T, Hasegawa N, Saya H, Wakui M, <u>Murata M</u> ,	Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff	Vaccine	40(7)	1019–1025	2022
Yamada Y, Yamada M, Chubachi S, Yokoayama Y, Matsuo S, Tana be A, Niiyama Y, Murata M, Abe T, Fukunaga K & Jinzaki M	Comparison of inspiratory and expiratory airway volumes and luminal areas among standing, sitting, and supine positions using upright and conventional CT	Scientific Reports	12(1)	21315	2022
Otake S, Chu bachi S, Nakayama S, Sakurai K, Irie H, Hashiguchi M, Itabashi Y, Yamada Y, Jinzaki M, <u>Murata M</u> , Nakamura H, Asano K, Fukunaga K	Clinical Utility of the Electrocardiographic P-Wave Axis in Patients with Chronic Obstructive Pulmonary Disease	Respiration	101(4)	345–352	2022
Uwamino Y, Nagata M, Aoki i W, Kato A, Daigo M, Ishihara O, Igari H, Inose R, Hasegawa N, <u>Murata M</u>	Efficient automated semi-quantitative urine culture analysis via BD Urine Culture App	Diagnostic Microbiology and Infectious Disease	102(1)	115567	2022

Yahagi K, Arai T, Katagiri H, Yatabe Y, Yokota H, Nagai Y, Mitsuhashi T, Wakui M, Murata M	Performance evaluation of a novel reticulocyte identification method that uses metachromatic nucleic acid staining based on a crossover analysis of emission DNA/RNA ligase (RNP Determination™) in hematology analyzer Celltac G+	International Journal of Laboratory Hematology	44(6)	1050-1059	2022
荒井智子、片桐尚子、近藤直美、谷田部陽子、横田浩充、永井豊、三ツ橋雄之、涌井昌俊、村田満	メタクロマジー核酸染色によるRNP法TMを用いたCelltac G+TM試作機の網赤血球算定の基礎的性能	日本検査血液学会雑誌	23 ( 2 )	265 – 273	2022
Kuwana M, Ito T, Kowata S, Hatta Y, Fujimaki K, Naito K, Kurahashi S, Kago T, Tanimoto K, Saotome S, Tomiyama Y, and R788-1301 Investigators.	Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study	Br J Haematol	200(6)	802-811	2023
Satoh T, Takiguchi H, Uojima H, Kubo M, Tanaka C, Yokoyama F, Wada N, Miyazaki K, Hidaka H, Kusano C, Kuwana M, and Horie R	B cell-activating factor is involved in thrombocytopenia in patients with liver cirrhosis	Ann Hematol	101(11)	2433-2444	2022
Nishikawa Y, Nishida S, Kuroda K, Kishiwagi H, Tomiyama Y and Kuwana M	Development of an automated chemiluminescent enzyme immunoassay for measuring thrombopoietin in human plasma	Diagnostics (Basel)	12(2)	313	2022

Yoshida K, S akaki A, Mat suyama Y, Mu shino T, Mat sumoto M, So noki T, Tamu ra S.	Acquired Thrombotic Thrombocytopenic Purpura Following Bime. NT162b2 mRNA Coronavirus Disease Vaccination in a Japanese Patient.	Internal medicine	61(3)	407–412	2022
Hamada E, Sa kai K, Yamad a S, Kubo M, Hayakawa M, <u>Matsumoto</u> M.	No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey.	Annals of hematology.	101(5)	1115–1117	2022
Uchino K, Sa kai K, Shino hara S, Mats uhisa A, Iid a Y, Nakano Y, Matsumura S, Kanasugi J, Takasugi S, Nakamura A, Horio T, Murakami S, Mizuno S, Yamamoto H, Hanamura I, <u>Matsumoto</u> M, Takami A.	Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature.	International journal of hematology.	116(2)	295–301	2022
Yokoo T, Tan abe A, Yoshi da Y, Caave ro JMM, Nak kido M, Ikeda a Y, Fujimur a Y, <u>Matsumo</u> nger K, Maru yama T, Okum ura CJ, Nang aku M, Tsumo to K.	Antibody recognition of complement Factor H reveals a flexible loop involved in Atypical Hemolytic Uremic Syndrome pathogenesis.	The Journal of biological chemistry.	101962–101962	101962–101962	2022

Kawano N, Abe T, Ikeda N, Nagahiro Y, Kawano S, Tochigi T, Nakaike T, Yamashita K, Kubo K, Yamamoto A, Terasaka S, Marutsuka K, Mshiba K, Kichichi I, Shimoda K, <u>Matsumoto</u> M, Ochiai H.	Clinical features and outcomes of four atypical hemolytic uremic syndrome cases at a single institution in Miyazaki Prefecture from 2015 to 2019.	Renal Replacement Therapy.	8(1)		2022
Yoshida K, Murata S, Shimoto M, Tanahashi T, Yamashita Y, Hosoi H, Nishikawa A, Tamura S, Hatakeyama K, <u>Matsumoto</u> M, Sonoki T.	Sudden Cardiac Death in a Patient with Thrombotic Thrombocytopenic Purpura: A Case Report.	Hematology reports.	14(2)	203–209	2022
Takagi Y, Kobayashi Y, Hirakata A, Iakei M, Awara S, Yajima C, Ikeuchi Y, Matsumoto A, Ogawa Y, Handa H, <u>Matsumoto</u> M, Arakawa H, Takizawa T.	Systemic Lupus Erythematosus Presenting With Thrombotic Thrombocytopenic Purpura at Onset: A Case Report.	Frontiers in Pediatrics.	10	931669–931669	2022
Sakai K, <u>Matsumoto</u> M, Walele L D, Dekimpe C, Hamada E, Kubo M, Tersteeg C, Meyer S D, Vanhooreel	ADAMTS13 conformation and immunoprofiles in Japanese patients with immunemediated thrombotic thrombocytopenic purpura.	Blood Adv.	7(1)	131–140	2022

Tarasco E, von Krogh AS, Hrdlickova R, Braschler TR, Iwaniec T, Knöbl P, Hamada E, Pikovsky O, Farese S, Gutwein O, Kessler P, Schultz NH, von Auer C, Windyga J, Friedman K, Hrachovinova I, George J N, Matsumoto M, Schneppenheim R, Läm	Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease.	Research and practice in thrombophilia and haemostasis	p6(7)	e12814	2022
Sakai K, Hamada E, Kokame K, Matsumoto M	Congenital thrombotic thrombocytopenic purpura: genetics and emerging therapies.	Annals of Blood	sd.		2022
Uwatoko R	Relapse of atypical hemolytic uremic syndrome triggered by COVID-19: a lesson for the clinical nephrologist.	J Nephrol	Mar 6	1-4	2023
Roth A, Barcellini W, Tvedt THA, et al.	Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study	Ann Hematol	101	2169–2177	2022
Yamazaki S, Naito E, Saniede R, et al.	Pure red cell aplasia accompanied by COVID-19 successfully treated with cyclosporine	J Infect chemoth	28	304–307	2022
Roth A, Bacarelli W, D’ Sa S, et al.	Complement 1S inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow up results	Haematologica	107	1698–1702	2022
Miyakawa Y, Imada K, Ichikawa S, et al.	The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study.	Int J Hematol	117	366–377	2022 Epub

宮川義隆	高齢者ITPに対するトロンボポエチン受容体作動薬の効果と安全性	血液内科	84	603–607	2022
宮川義隆	後天性血栓性血小板減少性紫斑病：リツキシマブを使用した症例	Land mark in thrombosis and hemostasis	2022	126–127	2022
日本小児・血液がん学会 血小板委員会	小児免疫性血小板減少症診療ガイドライン2022年版	日本小児・血液がん学会雑誌	59	50–57	2022
宮川義隆	妊娠関連TMA（HELLP症候群を含む）のコントロール	血液内科	85	191–194	2022
宮川義隆	後天性TPPの治療	日本血栓止血学会誌	33	414–420	2022
宮川義隆	カプラシズマブ：後天性血栓性血小板減少性紫斑病に血漿交換は不要になるか？	日本血栓止血学会誌	33	583–582	2022
安部涼平、 宮川義隆	新型コロナウイルスワクチンとITP	日本血栓止血学会誌	33	576–579	2022
宮川義隆	特発性血小板減少性紫斑病と血栓性血小板減少性紫斑病に対するリツキシマブ	リウマチ科	68	526–529	2022
Akiyama M, Eura Y, Kokame K	Siglec-5 and Siglec-14 mediate the endocytosis of ADAMTS13	Thromb Res	219	49–59	2022
Maruyama K, Miyata S, Kokame K	Alpha-HIT assay: A new assay for heparin-induced thrombocytopenia antibody detection using Fc $\gamma$ RIIa-coated beads and Alpha technology	Res Pract Thromb Haemost	6	e12818	2022
Sakai K, Hamada E, Kokame K, Matsumoto M	Congenital thrombotic thrombocytopenic purpura: genetics and emerging therapies	Ann Blood	2022	1–14	2022

Tsuji A, Miyata T, Sekine A, <u>Neki R,</u> <u>Kokame K,</u> Tomita T, Kashima Y, Asano R, Ueda J, Aoki T, Ogo T.	Three cases of unprovoked venous thromboembolism with prothrombin p.Arg596Gln variant and literature review of antithrombin resistance	Intern Med	62(6)	885–888	2023
Fukuma K, Yamagami H, Ihara M, Tanaka T, Miyata T, Miyata S, <u>Kokame K,</u> Nishimura K, Nakaoku Y, Yamamoto H, Hayakawa M, Kamiyama K, Enomoto Y, Itabashi R, Furui E, Manabe Y, Ezura M, Todo K, Hashikawa K, Uchiyama S, Toyoda K, Nagatsuka K.	P2Y12 reaction units and clinical outcomes in acute large artery atherosclerotic stroke: a multicenter prospective study	J Atheroscler Thromb	30(1)	39–55	2023
Urano T, Yas umoto A, Yok oyama K, Hor iuchi H, Mor ishita E, Su zuki Y.	COVID-19 and Thrombosis: Clinical Aspects.	Curr Drug Targets	23	1567–1572	2022

落合正行	周産期医学2022年4月増大号「Late preterm・Early termを展望する」 II. 各論：新生児編 7. 退院後の貧血予防	周産期医学	52	607-609	2022
松下正	【血液疾患のすべて】出血・血栓性疾患 von Willebrand 病	日本医師会雑誌	151	314-316	2022
Nishihori M, Araki Y, Suzuki N, Tamura S, Hattori M, Izumi T, Goto S, <u>Yokoyama K,</u> <u>Uda K,</u> <u>Matsushita T,</u> <u>Saito R.</u>	Medical Management of a Mural Thrombus Inducing Repeated Ischemic Strokes in a Patient with Congenital Afibrinogenemia.	J Stroke Cerebrovasc Dis.	28	620-629	2023
根木玲子	妊娠と静脈血栓症および治療量 抗凝固療法に関する研究	日本血栓止血学会誌	33(4)	448-456	2022